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1 INTRODUCTION 
 
Eating disorders are psychiatric disorders in which abnormal eating patterns are typical. In 
ICD-10 (1), anorexia nervosa (AN) is characterized by extreme fear of getting fat, 
bodyweight more than 15% below expected and amenorrhea. Bulimia nervosa (BN) is 
characterized with episodes of binging large amounts of food followed by self-induced 
vomiting, misuse of laxatives or fasting. In addition, dissatisfaction with one’s own body 
and fear of gaining weight are diagnostic features of BN (1). In DSM-4 and DSM-5 (2,3), 
typical features of binge-eating disorder (BED) are episodes of rapid uncontrolled food 
binges without the compensatory actions typical in BN. BED often leads to obesity, but can 
also occur in normal weight individuals. 
 
Malnutrition, especially protein-energy malnutrition, and some micronutrient deficiencies 
are generally associated with impaired immunity and increased incidence of infections (4). 
Some malnutrition is often present in eating disorders (5,6). As well as deficiencies, also 
excess intake of some micronutrients, such as zinc (7), and some energy yielding nutrients, 
like certain dietary fatty acids (8), is associated with impairment of the immune function. 
In obesity, immune function is often compromised, but the underlying factors are not fully 
understood. It has been suggested to result from excessive intake of some nutrients but 
also deficiencies of some micronutrients have been reported in obese people. In addition, 
metabolic and endocrine changes, typical in obesity, could alter the immune system. (7) 
On the other hand, individuals overweight or obese are at increased risk for developing 
disordered eating behaviors (9,10), and both BN and BED might be associated with 
overweight or obesity at the acute stages of the disorder. 
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Several studies have demonstrated alterations in the immune function in patients with 
AN. Mild leukopenia and anemia have commonly been associated with AN (11–14). These 
seem to improve in AN after refeeding (15). Similar results have been presented in 
patients with BN (5), although controversial results have also been published (16,17). 
Lymphocyte proliferative responses, i.e. lymphocytes ability to respond to various stimuli 
such as antigens or mitogens, have been shown to correlate negatively with the level of 
anxiety in BN (16).   
 
Reduced reactions or anegry, i.e. the secondary lack of cell mediated immunity, in delayed 
cutaneous hypersensitivity test, is common in patients with AN (11,12,18). In addition, 
reduction in the activation pathway, especially in T-lymphocytes CD2 and CD69, has been 
reported (15). Alterations in the function of the complement system of the immune 
defense have been associated both with AN and with obesity. Low bodyweight seems to 
associate with diminished complement proteins, whereas obesity is associated with the 
increased number of some proteins, for example complement proteins C3, B, AP50, H and 
I of the alternative pathway. (19,20)  
 
Despite the alterations of the immune system, patients with AN rarely seem to develop 
bacterial or viral infections  (14,21). This has been suggested to be due to the relatively 
good protein intake in many patients with AN (22). In addition, diminished febrile 
response in AN might complicate the diagnosis of infections and it might also be 
connected to increased complications (23,24). 
 
According to the knowledge of the author, no previous pharmacoepidemiological or other 
studies of the use of antimicrobial medications among patients with eating disorders exist. 
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This study aimed to assess the use of antimicrobial medication in patients suffering from 
AN, BN and BED in comparison with matched control population. The incidence and the 
number of prescriptions as well as defined daily doses (DDDs) in all groups were 
examined. To exclude the potential effect of the treatment for an eating disorder on the 
number of prescriptions prescribed to the patients compared to the controls, the use of 
antimicrobial medication was assessed for five-year time period before the treatment 
onset.  
 
Based on previous studies, the incidence and the number of prescriptions and DDDs were 
hypothesized to not differ in patients with AN compared to controls since the AN 
associated leukopenia have not been shown to increase the risk of infection; and, 
excluding Pediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcal infection (PANDAS), which includes early onset AN, infections are not 
known to trigger the disorder. The numbers of prescriptions and DDDs were hypothesized 
to be elevated in patients with BED due to the elevated prevalence of overweight and 
obesity in this population; and as described, obesity is associated with impairment of the 
immune function. Because of lack consistent previous findings in BN, the analyses were 
exploratory and there was no specific hypothesis of the direction of the change in this 
population. As described, patients with BN have been noticed to have similar changes in 
the immune system as patients with AN, but on the other hand large weight fluctuations 
and overweight might also be present in BN. 
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2 METHODS 
 
2.1 Study population 
The study included patients (N=1592) treated in the Eating Disorder Unit at the Helsinki 
University Central Hospital between January 1st, 2000 and December 31st, 2010. For the 
majority of patients the treatment was on outpatient level, but day patient and inpatient 
treatments were also available. For each patient, four control individuals (N=6368) 
matched by sex, age and place of residence were selected from the Central Population 
Register of Finland. Each individual follow-up period started five years before the onset of 
the treatment and lasted until the start of the treatment at the Eating Disorder Clinic.  
 
The diagnoses were made by the attending psychiatrist on the arrival at the Eating 
Disorder Unit on the grounds of International Classification of Disease (ICD-10) of the 
World Health Organization (1992) (1). The diagnostic groups within the patients were 
F50.0, F50.1, F50.2, F50.3 and F50.8 indicating AN, atypical AN, BN, atypical BN and BED, 
respectively. The diagnosis for atypical AN was made in case of patients who otherwise 
presented a fairly typical clinical picture of AN, but were missing one or more key features 
of the disorder; for example amenorrhea or weight loss below 85% of expected. Similarly, 
the diagnosis for atypical BN was made for patients who were missing one or more key 
features of BN, but otherwise presented a fairly typical clinical picture.  
 
For AN and BN broader definitions were used, since the current diagnostic criteria for 
eating disorders in DSM-5 (3) have been relaxed compared to DSM-4 (2) and ICD-10 (1). In 
this study ICD-10 classifications F50.0 and F50.1 indicate AN (N=701) and ICD-10 
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classifications F50.2 and F50.3 indicate BN (N=747). Patients with BED (F50.8; N=144) 
were diagnosed at the Eating Disorder Unit using the DSM-4 research criteria (2). 
 
2.2 Antimicrobial medication 
The study utilized the Medical Reimbursement Register of the Social Insurance Institution 
of Finland. The register includes data on all redeemed reimbursed prescriptions and 
individuals in this register can be identified by a personal identification number. These 
medication data were available from January 1st, 1995 to December 31st, 2011; all the 
study participants had medication data for five-year period before the onset of the 
treatment.  The numbers of prescriptions as well as DDDs were assessed.  DDD denotes a 
statistical value of average maintenance dose per day for a drug used for its main 
indication in adults, defined by the World Health Organization (25). Personal identification 
number was used for linkages between the study population and the data from the 
Medical Reimbursement Register on prescriptions of systemic antibacterial, antifungal and 
antiviral medication (Anatomical Therapeutic Chemical [ATC] groups J01, J02 and J05, 
respectively; see Appendix 1 for the list all drugs assessed). 
 
This study assessed the use of systemic antibacterial, antifungal and antiviral medication. 
Antibacterial drugs are used for defense against bacterial infections and can be targeted 
to effect on bacteria’s metabolism, cell wall synthesis, protein synthesis, nucleic acid 
synthesis or sometimes cell membrane permeability. Antifungal drugs are used against 
fungal infections usually caused by yeast, mold or dermatophyte. Many of the antifungal 
drugs prevent the synthesis of ergosterol, which is an essential component of the fungal 
cell wall. Virus is a strand of genetic material surrounded by a protein envelope. The 
majority of antiviral drugs are purine or pyrimidine analogs that compete with the natural 
components of the viral nucleic acids. (26) 
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2.3 Statistical analyses 
Conditional logistic regression model was used to analyze the difference in the prevalence 
of prescriptions between patients and matched controls with dichotomous manner (no 
prescription=0, one or more prescriptions=1). I.e., the numbers of prescriptions or DDDs 
were not taken into account in this test. Results are reported as odds ratios (ORs) with 
95% confidence intervals (CIs). 
 
Multivariate regression model was used to test the differences in DDDs in all ATC groups 
within each diagnostic group comparing the patients to the control population. To 
compare the prevalence of prescriptions within patients in three diagnostic groups, 
logistic regression analysis was used and AN group was used as the reference. Results are 
reported as ORs with 95% CI. Also prevalence adjusted by sex and age were modeled. 
 
Because of the overdispersed data, quasipoisson regression model was used to make 
predictions on the number of prescriptions for individuals of different age and sex. This 
quasi-likelihood allows greater variability in the data than would be predicted by the 
Poisson model (27). Linear regression model was used to assess the number of DDDs 
during the five-year follow-up period. DDD was set as the dependent variable and age, sex 
and diagnostic groups were set as the independent variables. Predictions of the estimated 
values for individuals of different age and sex were calculated using these models. Results 
are presented as predictions with 95% CIs. 
The author performed all the analyses using R software. 
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2.4 Ethical considerations 
Ethical permits for the study were obtained from the Ethics committee of National 
Institute of Health and Welfare (Dnro THL/184/6.02.00/2011), and the permission of the 
use of the data of The Social Security Institution was obtained. The study was conducted 
according to the Helsinki Declaration. Data handling was performed according to the 
Finnish data protection legislation and the rules of National Institute of Health and 
Welfare. The author did not have access to the personal identification data, only research 
codes were used in the analyses. 
 
 
 
3 RESULTS 
 
3.1 Basic characteristics of the study population 
The basic characteristics of the patients of the study population are presented in Table 1. 
The study population consisted of 1592 patients (1515 females and 68 males) and 6368 
control individuals (6096 females and 272 males). There were 701 (4.71% males) patients 
with AN, 747 (2.01% males) patients with BN and 144 (13.89% males) patients with BED. 
The mean age of the whole population was 26.0 years (SD ±8.4); 23.6 years (SD ±6.9) in 
patients with AN, 25.9 (SD ±7.2) in patients with BN and 38.0 (SD ±10.5) in patients with 
BED. 
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Table 1. Basic characteristics of the patients of the study population by diagnostic groups. 
The age of the patients was recorded at the beginning of the treatment at the Eating 
Disorder Unit of the Helsinki University Central Hospital. 
SD, Standard Deviation 
 
 All eating disorders Anorexia nervosa 
(F50.0+F50.1) 
Bulimia nervosa 
(F50.2+F50.3) 
Binge-eating disorder 
(F50.8) 
 Patients 
(N) 
% Patients 
(N) 
% Patients 
(N) 
% Patients (N) % 
Number 1592 100.00% 701 100 747 100.00% 144 100.00% 
Sex         
Female 1515 95.16% 668 95.29% 723 96.79% 124 86.11% 
Male 68 4.27% 33 4.71% 15 2.01% 20 13.89% 
Age 
groups, 
years 
        
(0,20] 385 24.18% 252 35.95% 130 17.40% 3 2.08% 
(20,25] 565 35.49% 263 37.52% 291 38.96% 11 7.64% 
(25,30] 285 17.90% 97 13.84% 171 22.89% 17 11.81% 
(30,35] 147 9.23% 39 5.56% 80 10.71% 28 19.44% 
(35,40] 78 4.90% 18 2.57% 32 4.28% 28 19.44% 
(40,45] 58 3.64% 14 2.00% 21 2.81% 23 15.97% 
(45,50] 40 2.51% 12 1.71% 14 1.87% 14 9.72% 
(50,Inf] 34 2.14% 6 0.86% 8 1.07% 20 13.89% 
         
 Mean ± SD  Mean ± SD  Mean ± SD  Mean ± SD  
Age, 
years 
26.0±8.4  23.6±6.9  25.9±7.2  38.0±10.5  
Min. 17.4  17.4  17.6  18.7  
Q1 20.1  19.2  20.8  30.6  
Med. 23.2  21.1  24.0  36.8  
Q3 28.8  25.3  28.8  44.6  
Max. 64.8  64.8  64.5  64.2  
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3.2 The numbers of prescriptions and defined daily doses 
Appendix 1 summarizes the numbers of prescriptions and DDDs with the mean values in 
each diagnostic group of all the drugs assessed in the study. The total number of 
prescriptions in this study was 25 869 (mean 3.25 prescriptions per person) and the total 
number of DDDs was 263 533 (mean 33.11 DDDs per person).  
 
In multivariate regression analyses, patients had more DDDs than the controls as follows. 
There was significantly higher number of DDDs of all drugs together in patients with BN 
and BED (P<0.001 and P<0.001, respectively) compared to the controls. There was also 
significantly larger number of DDDs in both BN and BED groups when assessing all 
antibacterial drugs together (P<0.001 and P<0.001, respectively) and specifically, 
tetracyclines (ATC code J01A; P<0.001 and P<0.001), beta-lactam antibacterials, i.e. 
penicillins (ATC code J01C; P= 0.05 and P= 0.04) and other beta-lactam antibacterials (ATC 
code J01D; P= 0.008 and P<0.001). In addition, there was more DDDs of macrolides, 
lincosamides and streptogramins (ATC code J01F) in the BN group (P= 0.005) and 
quinolone antibacterials (ATC code J01M) in the BED group (P= 0.04). BED patients had 
also significantly more DDDs of antifungal drugs (ATC code J02) than the controls (P= 
0.03).  
 
Of the individual drugs, there was increased number of DDDs in doxycycline (ATC code 
J01AA02; P=0.03), amoxicillin (ATC code J01CA04; P= 0.05), cephalexin (ATC code 
J01DB01; P=0.01) and fluconazole (ATC code J02AC01; P= 0.02) in the BN diagnostic group. 
In the BED diagnostic group, there was increased number of DDDs in phenoxymethyl 
penicillin (ATC code J01CE02; P= 0.02) and cephalexin (ATC code J01DB01; P<0.001). There 
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were no significant differences between AN patients and controls except in ATC group 
J01F indicating macrolides, lincosamides and streptogramins (P=0.005).  
 
3.3 The use of antimicrobial medication 
The results of conditional logistic regression analyses are presented in Table 2. In addition, 
the numbers of patients positive and negative for prescriptions with the percentage of the 
positive are presented. Assessing all prescriptions as a composite showed significantly 
higher prevalence of prescriptions in all patients compared to the matched controls (OR 
1.22, 95% CI 1.06 - 1.40, P= 0.004). Patients with BED had the highest prevalence of all 
prescription (OR 2.58, 95% CI 1.44 - 4.61, P= 0.001), of antibacterial prescriptions (OR 2.37, 
95% CI 1.39 - 4.06, P=0.002) and of antifungal prescriptions (OR 1.70, 95% CI 1.09 - 2.66, 
P= 0.02).  
 
BN patients had significantly higher prevalence of prescriptions compared to their 
matched controls in all drug groups assessed, and BN group was the only eating disorder 
group showing significant difference in antiviral drugs (OR 1.61, 95% CI 1.14 - 2.29, P= 
0.007). There was no difference between patients with AN and their controls in any of the 
drug groups. 
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Table 2. The prevalence of prescriptions in patients with different eating disorders 
compared to the matched controls. The numbers of patients positive and negative for 
prescriptions (YES/NO) with the percentage of the positive are presented as well as odds 
ratios with 95% confidence interval and P-values.   
OR, Odds Ratio; CI, Confidence Interval 
 N (positive/negative for prescription, % of 
positive) 
OR (95% CI) P-value 
 Patients Controls   
All Prescriptions YES NO % YES NO %   
All eating disorders 1260 332 79.15% 4825 1543 75.77% 1.21 (1.06 - 1.40) 0.004 
Anorexia Nervosa 499 202 71.18% 2082 722 74.25% 0.85 (0.71 - 1.03) 0.100 
Bulimia Nervosa 632 115 84.61% 2296 692 76.84% 1.67 (1.34 - 2.07) <0.001 
Binge Eating Disorder 129 15 89.58% 447 129 77.60% 2.58 (1.44 - 4.61) 0.001 
Prescriptions of 
Antibacterial Drugs 
        
All eating disorders 1225 367 76.95% 4692 1676 73.68% 1.20 (1.05 - 1.36) 0.007 
Anorexia Nervosa 490 211 69.90% 2035 769 72.57% 0.88 (0.73 - 1.05) 0.200 
Bulimia Nervosa 609 138 81.53% 2224 764 74.43% 1.52 (1.24 - 1.86) 0.001 
Binge Eating Disorder 126 18 87.50% 433 143 75.17% 2.37 (1.39 - 4.06) 0.002 
Prescriptions of 
Antifungal Drugs 
        
All eating disorders 293 1299 18.40% 1037 5331 16.28% 1.17 (1.01 - 1.35) 0.040 
Anorexia Nervosa 83 618 11.84% 395 2409 14.09% 0.81 (0.63 - 1.05) 0.100 
Bulimia Nervosa 170 577 22.76% 531 2457 17.77% 1.38 (1.13 - 1.68) 0.002 
Binge Eating Disorder 40 104 27.78% 111 465 19.27% 1.70 (1.09 - 2.66) 0.020 
Prescriptions of 
Antiviral Drugs 
        
All eating disorders 73 1519 4.59% 254 6114 3.99% 1.16 (0.886 - 1.51) 0.300 
Anorexia Nervosa 18 683 2.57% 93 2711 3.32% 0.77 (0.46 - 1.28) 0.300 
Bulimia Nervosa 47 700 6.29% 120 2868 4.02% 1.61 (1.14 - 2.29) 0.007 
Binge Eating Disorder 8 136 5.56% 41 535 7.12% 0.76 (0.35 - 1.68) 0.500 
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Logistic regression analyses results are shown in Table 3. There was a higher prevalence of 
prescriptions in patients with BN and BED compared to the patients with AN (used as 
reference). The prevalence was higher also when adjusted by sex and age. 
Table 3. Results of logistic regression analyses of the prevalence of prescription presented 
as odds ratios with 95% confidence intervals with and without adjustments by sex and 
age. Patients with anorexia nervosa were used as reference. 
OR, Odds Ratio; CI, Confidence Interval 
  Adjusted by sex and age 
 OR (95% CI)  OR (95% CI) 
Prescriptions of All Antimicrobial Drugs 
  Sex, female 1.57 (0.88 - 2.80) 
  Age 1.02 (1.00 - 1.04) 
Bulimia nervosa 2.23 (1.72 - 2.88) Bulimia nervosa 2.12 (1.63 - 2.75) 
Binge-eating disorder 3.48 (1.99 - 6.09) Binge-eating disorder 2.91 (1.58 - 5.37) 
Prescriptions of Antibacterial Drugs 
  Sex, female 1.34 (0.76 - 2.39) 
  Age 1.01 (0.99 - 1.03) 
Bulimia nervosa 1.90 (1.49 - 2.43) Bulimia nervosa 1.84 (1.43 - 2.36) 
Binge-eating disorder 3.01 (1.79 - 5.07) Binge-eating disorder 2.67 (1.51 - 4.72) 
Prescriptions of Antifungal Drugs 
  Sex, female 7.02 (2.14 - 23.09) 
  Age 1.03 (1.02 - 1.05) 
Bulimia nervosa 2.19 (1.65 - 2.92) Bulimia nervosa 2.00 (1.50 - 2.67) 
Binge-eating disorder 2.86 (1.86 - 4.41) Binge-eating disorder 2.04 (1.24 - 3.34) 
Prescriptions of Antiviral Drugs 
  Sex, female 2.28(0 - Inf) 
  Age 1.02 (0.99 - 1.05) 
Bulimia nervosa 2.55 (1.47 - 4.43) Bulimia nervosa 2.36 (1.35 - 4.12) 
Binge-eating disorder 2.23 (0.95 - 5.24) Binge-eating disorder 1.82 (0.70 - 4.75) 
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3.4 Predictions of the use of antimicrobial medication 
Quasipoisson model was used to make predictions of the number of antimicrobial 
prescriptions prescribed for individuals during the five-year time period (Table 4). The 
predicted numbers of prescriptions were higher for females than for males (P<0.001) 
(Appendix 2). The number of prescriptions rose with age (P<0.001) (Appendix 2). The 
predicted number of prescriptions was highest in BED patients; 5.15 antimicrobial 
prescriptions (95% CI 4.41 - 6.02) for a 25-year-old female compared to 3.13 prescriptions 
(95% CI 3.03 - 3.23) for a control of a same age. A female BN patient of 25 years of age had 
a prediction of 4.05 prescriptions (95% CI 3.74 - 4.38) during the five-year time period. The 
patients with AN did not differ significantly from the controls when assessing all 
antimicrobial prescriptions; the prediction for a 25-year old female was 2.92 prescriptions 
(95% CI 2.64 - 3.22). The only significant difference in patients with AN was in antifungal 
prescriptions that they had less than the controls (P=0.03).  
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Table 4. The predicted numbers of prescriptions in the course of five years for 20-, 25- and 
40-year-old females and males with 95% confidence intervals.  
CI, Confidence Interval 
 
 
 20-year-old female 25-year-old female 40-year-old female 
 Number of 
prescriptions (95% CI) 
Number of 
prescriptions (95% CI) 
Number of 
prescriptions (95% CI) 
All Antimicrobial Drugs    
Controls 2.88 (2.77 - 2.99) 3.13 (3.03 - 3.23) 4.01 (3.82 - 4.22) 
Anorexia nervosa 2.68 (2.43 - 2.97) 2.92 (2.64 - 3.22) 3.75 (3.36 - 4.18) 
Bulimia nervosa 3.72 (3.43 - 4.04) 4.05 (3.74 - 4.38) 5.20 (4.75 - 5.68) 
Binge-eating disorder 4.74 (4.04 - 5.56) 5.15 (4.41 - 6.02) 6.62 (5.70 - 7.68) 
Antibacterial Drugs    
Controls 2.52 (2.43 - 2.62) 2.68 (2.60 - 2.76) 3.22 (3.06 - 3.39) 
Anorexia nervosa 2.40 (2.18 - 2.64) 2.55 (2.32 - 2.80) 3.06 (2.75 - 3.41) 
Bulimia nervosa 3.13 (2.89 - 3.40) 3.33 (3.08 - 3.60) 4.00 (3.66 - 4.37) 
Binge-eating disorder 4.00 (3.41 - 4.70) 4.26 (3.64 - 4.98) 5.11 (4.39 - 5.94) 
Antifungal Drugs    
Controls 0.29 (0.26 - 0.32) 0.35 (0.32 - 0.38) 0.58 (0.52 - 0.65) 
Anorexia nervosa 0.08 (0.05 - 0.15) 0.25 (0.18 - 0.33) 0.41 (0.30 - 0.57) 
Bulimia nervosa 0.14 (0.09 - 0.22) 0.52 (0.43 - 0.63) 0.87 (0.71 - 1.08) 
Binge-eating disorder 0.05 (0.02 - 0.18) 0.80 (0.58 - 1.10) 1.33 (0.98 - 1.81) 
Antiviral Drugs    
Controls 0.07 (0.06 - 0.09) 0.09 (0.07 - 0.11) 0.19 (0.15 - 0.24) 
Anorexia nervosa 0.08 (0.05 - 0.15) 0.11 (0.06 - 0.20) 0.22 (0.12 - 0.42) 
Bulimia nervosa 0.14 (0.09 - 0.22) 0.18 (0.12 - 0.28) 0.38 (0.24 - 0.59) 
Binge-eating disorder 0.05 (0.02 - 0.18) 0.07 (0.02 - 0.23) 0.14 (0.04 - 0.46) 
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 20-year-old male 25-year old male 40-year-old male 
 Number of 
prescriptions (95% CI) 
Number of 
prescriptions (95% CI) 
Number of 
prescriptions (95% CI) 
All Antimicrobial Drugs    
Controls 1.47 (1.23 - 1.76) 1.60 (1.34 - 1.90) 2.05 (1.73 - 2.44) 
Anorexia nervosa 1.37 (1.13 - 1.67) 1.49 (1.23 - 1.81) 1.91 (1.57 - 2.33) 
Bulimia nervosa 1.90 (1.57 - 2.31) 2.07 (1.71 - 2.50) 2.66 (2.20 - 3.21) 
Binge-eating disorder 2.42 (1.92 - 3.06) 2.63 (2.10 - 3.31) 3.38 (2.72 - 4.21) 
Antibacterial Drugs    
Controls 1.49 (1.27 - 1.27) 1.59 (1.35 - 1.86) 1.91 (1.63 - 2.23) 
Anorexia nervosa 1.42 (1.18 - 1.71) 1.51 (1.26 - 1.81) 1.81 (1.51 - 2.18) 
Bulimia nervosa 1.85 (1.55 - 2.22) 1.97 (1.65 - 2.35) 2.37 (1.98 - 2.82) 
Binge-eating disorder 2.37 (1.90 - 2.96) 2.52 (2.03 - 3.13) 3.02 (2.45 - 3.73) 
Antifungal Drugs    
Controls 0.03 (0.01 - 0.08) 0.04 (0.02 - 0.09) 0.07 (0.03 - 0.15) 
Anorexia nervosa 0.02 (0.01 - 0.06) 0.03 (0.01 - 0.07) 0.05 (0.02 - 0.12) 
Bulimia nervosa 0.05 (0.02 - 0.12) 0.06 (0.02 - 0.14) 0.10 (0.04 - 0.24) 
Binge-eating disorder 0.08 (0.03 - 0.19) 0.09 (0.04 - 0.22) 0.15 (0.06 - 0.37) 
Antiviral Drugs    
Controls 0.02 (0.01 - 0.08) 0.03 (0.01 - 0.09) 0.05 (0.02 - 0.19) 
Anorexia nervosa 0.02 (0.01 - 0.10) 0.03 (0.01 - 0.12) 0.06 (0.02 - 0.25) 
Bulimia nervosa 0.04 (0.01 - 0.16) 0.05 (0.01 - 0.20) 0.11 (0.03 - 0.40) 
Binge-eating disorder 0.02 (0.00 - 0.09) 0.02 (0.00 - 0.11) 0.04 (0.01 - 0.22) 
 
 
Linear regression model was used to make predictions of the number of DDDs. As in 
quasipoisson model, the results are presented as predicted numbers of DDDs with 95% CI 
for 20-, 25- and 40-year-old females and males in table 5. The predicted number of all 
DDDs for a 25-year-old female with BED is 62.1 (95% CI 51.7 - 72.6), which is nearly double 
to the number of a control of a same age with 31.8 DDDs (95% CI 30.3 - 33.4). BN patient 
had a prediction of a total of 42.4 DDDs (95% CI 37.9 - 46.8), which is significantly higher 
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than the prediction for a control. Patients with AN did not have significantly different 
prediction of DDDs in any drug groups tested with linear regression model. The number of 
DDDs rose with age and females had higher number of DDDs than males. (Appendix 3) 
 
Table 5. Predicted numbers of defined daily doses in the course of five years for 20-, 25- 
and 40-year-old females and males with 95% confidence intervals. 
DDD, Defined Daily Dose; CI, Confidence Interval 
 
 20-year-old female 25-year-old female 40-year-old female 
 Number of DDDs (95%CI) Number of DDDs (95%CI) Number of DDDs (95%CI) 
All Antimicrobial 
Drugs 
   
Controls 30.5 (28.6 - 32.3) 31.8 (30.3 - 33.4) 35.8 (32.9 - 38.7) 
Anorexia nervosa 32.2 (27.6 - 36.9) 33.6 (28.9 - 38.2) 37.6 (32.1 – 43.0) 
Bulimia nervosa 41.0 (36.4 - 45.6) 42.4 (37.9 - 46.8) 46.3 (41.2 - 51.4) 
Binge-eating disorder 60.8 (50.1 - 71.5) 62.1 (51.7 - 72.6) 66.1 (55.8 - 76.4) 
Antibacterial Drugs    
Controls 29.9 (28.1 - 31.6) 30.6 (29.1 - 32.1) 32.8 (30.0 - 35.5) 
Anorexia nervosa 31.3 (26.8 - 35.8) 32.0 (27.6 - 36.5) 34.2 (29.0 - 39.4) 
Bulimia nervosa 40.2 (35.8 - 44.6) 40.9 (36.6 - 45.2) 43.1 (38.2 - 47.9) 
Binge-eating disorder 55.4 (45.2 - 65.6) 56.2 (46.1 - 66.2) 58.3 (48.5 - 68.2) 
Antifungal Drugs    
Controls 0.5 (0.3 - 0.7) 0.9 (0.7 – 1.0) 2.0 (1.7 - 2.2) 
Anorexia nervosa 0.5 (0.0 - 0.9) 0.9 (0.4 - 1.3) 1.9 (1.4 - 2.5) 
Bulimia nervosa 0.7 (0.2 - 1.1) 1.0 (0.6 - 1.5) 2.1 (1.6 - 2.6) 
Binge-eating disorder 3.3 (2.3 - 4.3) 3.7 (2.7 - 4.7) 4.8 (3.8 - 5.8) 
Antiviral Drugs    
Controls 0.2 (0.0 - 0.3) 0.3 (0.2 - 0.5)           0.8 (0.6 - 1.1) 
Anorexia nervosa 0.5 (0.0 – 1.0) 0.7 (0.2 - 1.1) 1.2 (0.6 - 1.7) 
Bulimia nervosa 0.3 (-0.2 - 0.7) 0.4 (0.0 - 0.9) 0.9 (0.4 - 1.5) 
Binge-eating disorder 0.2 (-0.9 - 1.2) 0.3 (-0.7 - 1.4) 0.9 (-0.2 - 1.9) 
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 20-year-old male 25-year-old male 40-year-old male 
 Number of DDDs (95%CI) Number of DDDs (95%CI) Number of DDDs (95%CI) 
All Antimicrobial 
Drugs 
   
Controls 14.8 (7.8 - 21.8) 16.1 (9.3 - 23) 20.1 (13.3 - 27) 
Anorexia nervosa 16.6 (8.4 - 24.7) 17.9 (9.9 - 25.9) 21.9 (13.7 - 30.0) 
Bulimia nervosa 25.3 (17.0 - 33.6) 26.7 (18.5 - 34.8) 30.7 (22.5 - 38.8) 
Binge-eating disorder 45.1 (32.6 - 57.6) 46.4 (34.2 - 58.6) 50.4 (38.6 - 62.2) 
Antibacterial Drugs    
Controls 15.8 (9.1 - 22.5) 16.5 (10.0 - 23.0) 18.7 (12.2 - 25.2) 
Anorexia nervosa 17.2 (9.4 - 25.0) 17.9 (10.3 - 25.6) 20.1 (12.3 - 27.9) 
Bulimia nervosa 26.1 (18.1 - 34.0) 26.8 (19.0 - 34.6) 29.0 (21.2 - 36.8) 
Binge-eating disorder 41.4 (29.4 - 53.3) 42.1 (30.4 - 53.8) 44.3 (33.0 - 55.6) 
Antifungal Drugs    
Controls -0.4 (-1.1 - 0.3) 0.0 (-0.7 - 0.6) 1.1 (0.4 - 1.7) 
Anorexia nervosa -0.4 (-1.2 - 0.4) -0.1 (-0.8 - 0.7) 1.0 (0.3 - 1.8) 
Bulimia nervosa -0.2 (-1.0 - 0.6) 0.1 (-0.7 - 0.9) 1.2 (0.4 - 2.0) 
Binge-eating disorder 2.4 (1.2 - 3.6) 2.8 (1.6 - 3.9) 3.9 (2.7 - 5.0) 
Antiviral Drugs    
Controls -0.3 (-1.0 - 0.4) -0.1 (-0.8 - 0.6) 0.4 (-0.3 - 1.1) 
Anorexia nervosa 0.0 (-0.8 - 0.8) 0.2 (-0.6 - 1.0) 0.7 (-0.1 - 1.5) 
Bulimia nervosa -0.2 (-1.0 - 0.6) 0.0 (-0.8 - 0.8) 0.5 (-0.3 - 1.3) 
Binge-eating disorder -0.3 (-1.5 – 1.0) -0.1 (-1.3 - 1.1) 0.4 (-0.8 - 1.6) 
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4 DISCUSSION 
 
This study demonstrated that the patients with BN and BED had higher prevalence and 
higher number of prescriptions and DDDs compared to the control population in many 
antimicrobial drug groups. Compared to the controls, patients with BED had substantially 
higher prevalence and larger number of antibacterial and antifungal prescriptions as well 
as larger number of DDDs of those drug groups. Patients with BN had higher prevalence 
and number of antibacterial, antifungal and antiviral prescriptions and larger number of 
DDDs of antibacterial and antiviral drugs. Generally AN patients seemed to have less 
prescriptions and DDDs than their controls, the results did not however reach the 
statistical significance except in the number of antifungal prescriptions. The numbers of 
prescriptions and DDDs were higher among females than males in the whole study 
population, except in antiviral drugs. The findings of this study provide support for the 
association between eating disorders with binge-eating patterns and the increased 
number of infections.  
 
The prevalence of antimicrobial drug prescriptions and DDDs can be considered as an 
indicator of the number of infections. BED is often, but not always, associated with 
overweight or obesity. This might partly explain the highly increased use of antimicrobial 
medication within patients with BED, since overweight and obesity are linked to increased 
number of infections (4,7). During the five-year follow up in this study, BED patients had 
nearly double the number of DDDs of anti-bacterial drugs and 2.6 times more DDDs of 
antifungal drugs than the controls. There was no prominent increase in the number of 
antiviral prescriptions in patients with BED, which might be due to the generally lower 
tendency to prescribe antiviral drugs. Various physical and psychiatric health problems, 
such as diabetes, depression and anxiety disorders, associate with binge-eating (28). 
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Comorbidity of binge-eating and psychiatric disorders has been shown to be independent 
of BMI (29). Depression has been reported to be linked to the activation of the immune 
system (30).  
 
Of all the eating disorder groups, patients with BED had the highest prevalence of 
prescription in all other drug groups except for antiviral drugs, even when adjusted by age 
and sex. BED and BN patients had higher number of DDDs of antifungal drugs than the 
controls. Binge-eating considerably increases the blood sugar levels and hyperglycemia, at 
least in diabetes mellitus, has been associated with the higher prevalence of oral Candida 
infections (31) and also deaths caused by candidaemia, i.e. invasive candidiasis (32). B 
lymphocyte function has been reported to be impaired in high glucose concentrations 
(33). In addition, surgical patients with postsurgical non-diabetic hyperglycemia seem to 
develop more surgical site infections than the patients without hyperglycemia (34,35). 
Acute hyperglycemia after overfeeding in non-diabetic rats also promotes the 
inflammation in severe infections (36). The high acute blood glucose levels caused by 
binge-eating might therefore explain the elevated number of infections and hence the use 
of antimicrobial medication in patients with BN and BED. 
 
BN was the only diagnostic group with higher prevalence of antiviral drug prescriptions. 
Aciclovir was the only individual antiviral drug assessed in this study, and in adults it is 
mainly used systemically as an acute or preventive medication in Herpes simplex virus 
(HSV) infections or sometimes against shingles or chickenpox (26). Herpes simplex virus 
has two subtypes: HSV-1, which produces most cold sores, and HSV-2, which produces 
most genital herpes. BN has been associated with early puberty and early sexual activity 
(37) as well as childhood sexual abuse (38). Individuals with BN, and especially those with 
early sexual abuse, are prone to have multi-impulsivity (38,39), which is characterized by 
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another impulsive behavior, such as alcohol or drug abuse or sexual disinhibition. In 
addition, association between extreme weight control methods and unprotected sexual 
activity have been reported (40). Together with previous studies, our results suggest that 
patients with BN are at increased risk for sexually transmitted HSV-2 infections.  
 
Previous studies (14,21) have shown that patients with AN do not seem to develop more 
infections than the control population. This is in line with the results of this study where 
patients with AN did not have any more prescriptions or DDDs of systemic antimicrobial 
drugs than the matched controls. This might be due to the relatively good protein intake 
in many patients with AN (22) since especially protein-energy malnutrition is associated 
with increased amount of infections (4). Diminished febrile response in AN might also 
complicate the diagnosis of infections (23,24). It has been suggested that streptococcal 
infections might play a role in the development of some subtypes of early onset AN 
(PANDAS-AN) (42). In addition, elevated proinflammatory cytokines, such as tumor 
necrosis factor (TNF)-α, have been hypothesized to contribute to the development of 
psychiatric disorders like depression, anxiety and AN (43,44). Also some physical diseases, 
such as cardiac and autoimmune diseases, have been hypothesized to develop by the 
interaction between immune system and central nervous system (45). The low numbers of 
prescriptions and DDDs in the patients with AN before the treatment in this study 
suggests that the infection-triggered inflammation do not play a major role in the 
development of AN on a larger population, even though it might be true in some 
individual cases. However, it is possible that increased amount of infections, revealed in 
BN and BED patients, precedes the eating disorders with binge-eating patterns. The 
immunological (5) and inflammatory (41) changes present in eating disorders could be the 
possible initiators of binge-eating, since, as mentioned, proinflammatory cytokines might 
be involved in the development of some psychiatric disorders.  
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4.1 Strengths and limitations 
The strengths of this study were the large patient sample with different eating disorders 
and the relatively long follow-up period of five years preceding the treatment. Assessing 
the use of antimicrobial medication before the start of the treatment made it possible to 
rule out the potential influence of the treatment on the amount of prescriptions in 
patients compared to the controls, who were not necessarily under a regular medical 
observation. 
 
The most important limitation of this study is the dearth of information about the date of 
the onset of a patient’s eating disorder. There was no certainty on how long a patient had 
the eating disorder before the start of the treatment and therefore how long of a period 
of the five-year follow-up each individual had the disorder. The limitations also include the 
lack of BMI information about the patients and their controls. However, according to the 
experience at the Eating Disorder Unit, the majority of the patients with BN were within 
the normal weight range (BMI 18.5-24.9), whereas most of the patients with BED were 
overweight (BMI 25.0-29.9) or obese (BMI ≥30.0). In addition, the long follow-up period 
decreases the significance of the lacking BMI information, since large weight fluctuations 
are very common among patients with eating disorders. 
 
4.2 Conclusion 
In conclusion, the results of this study showed increased use of antimicrobial medication 
in patients with BN and BED. This indicates the elevated number of infections in these 
patient groups, which might be a consequence of hyperglycemia caused by binge-eating. 
On the other hand, increased number of infections, and thus inflammation mediators, 
might contribute to the onset of binge-eating. The future studies should concentrate on 
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the underlying mechanisms causing increased number of infections in patients with binge-
eating behavior as well as the possible effect of infections and inflammatory mediators on 
the pathophysiology of binge-eating. 
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APPENDICES 
Appendix 1. The numbers and means of prescriptions and defined daily doses of all the 
drugs assessed in the study in patients with eating disorders and in controls. The 
significant differences between patients and controls in multivariate regression analyses 
on the number of DDDs are bolded with *. 
ATC, Anatomical Therapeutic Chemical; DDD, defined daily dose 
 
Drug or a drug group 
(ATC code) 
 All eating 
disorders and 
controls 
Anorexia nervosa Bulimia nervosa Binge-eating disorder 
    Patients Controls Patients Controls Patients Controls 
 N Mean N Mean N Mean N Mean N Mean N Mean N Mean 
All drugs               
 Prescriptions 25869 3.25 1964 2.80 8181 2.92 3058 4.09 9573 3.20 868 6.03 2225 3.86 
 DDDs 263533 33.11 22760 32.47 87212 31.10 31582 42.28* 93321 31.23* 9130 63.41* 19528 33.9* 
Antibacterial drugs               
All (J01) Prescriptions 21957 2.76 1729 2.47 7214 2.57 2503 3.35 8064 2.70 681 4.73 1766 3.07 
DDDs 252206 31.68 21842 31.16 84646 30.19 30426 40.73* 89469 29.94* 8077 56.09* 17747 30.81* 
Tetracyclines (J01A) Prescriptions 3485 0.44 323 0.46 1144 0.41 447 0.60 1224 0.41 104 0.72 243 0.42 
DDDs 100553 12.63 9929 14.16 35535 12.67 13307 17.81* 33715 11.28* 2999 20.83* 5069 8.80* 
Doxycycline (J01AA02) Prescriptions 1813 0.23 123 0.18 518 0.18 220 0.29 703 0.24 61 0.42 188 0.33 
DDDs 26771 3.36 1859 2.65 7620 2.72 3410 4.56* 10232 3.42* 843 5.85 2809 4.88 
Beta-lactam 
antibacterials, 
penicillins (J01C) 
Prescriptions 6640 0.83 536 0.76 2412 0.86 715 0.96 2368 0.79 157 1.09 452 0.78 
DDDs 65676 8.25 5199 7.42 23529 8.39 6965 9.32* 23644 7.91* 1622 11.27* 4716 8.19* 
Amoxicillin (J01CA04) Prescriptions 2889 0.36 246 0.35 1016 0.36 336 0.45 1018 0.34 75 0.52 198 0.34 
DDDs 34228 4.30 2813 4.01 11752 4.19 3945 5.28* 12471 4.17* 836 5.81 2411 4.19 
Pivmecillinam (J01CA08) Prescriptions 1057 0.13 75 0.11 418 0.15 103 0.14 381 0.13 17 0.12 63 0.11 
DDDs 7370 0.93 508 0.72 2828 1.01 714 0.96 2756 0.92 116 0.80 448 0.78 
Phenoxymethylpenicillin 
(J01CE02) 
Prescriptions 1854 0.23 142 0.20 656 0.23 219 0.29 690 0.23 39 0.27 108 0.19 
DDDs 14486 1.82 1042 1.49 5158 1.84 1686 2.26 5350 1.79 378 2.63* 871 1.51* 
Amoxicillin and enzyme 
inhibitor (J01CR02) 
Prescriptions 814 0.10 72 0.10 310 0.11 55 0.07 271 0.09 24 0.17 82 0.14 
DDDs 9310 1.17 828 1.18 3604 1.29 605 0.81 3022 1.01 272 1.89 979 1.70 
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Drug or a drug group 
(ATC code) 
 All eating 
disorders and 
controls 
Anorexia nervosa Bulimia nervosa Binge-eating disorder 
    Patients Controls Patients Controls Patients Controls 
 N Mean N Mean N Mean N Mean N Mean N Mean N Mean 
Antibacterial drugs                
Other beta-lactam 
antibacterials (J01D) 
Prescriptions 5110 0.64 358 0.51 1645 0.59 584 0.78 1935 0.65 183 1.27 405 0.70 
DDDs 31485 3.96 2138 3.05 10082 3.60 3466 4.64* 11491 3.85* 1669 11.59* 2639 4.58* 
Cephalexin (J01DB01) Prescriptions 4378 0.55 306 0.44 1404 0.50 507 0.68 1644 0.55 166 1.15 351 0.61 
DDDs 26442 3.32 1765 2.52 8461 3.02 2891 3.87* 9510 3.18* 1565 10.87* 2250 3.91* 
Sulfonamides and 
trimethoprim (J01E) 
Prescriptions 881 0.11 53 0.08 286 0.10 106 0.14 345 0.12 24 0.17 67 0.12 
DDDs 10583 1.33 810 1.16 3226 1.15 1178 1.58 4477 1.50 193 1.34 699 1.21 
Macrolides, 
lincosamides and 
streptogramins (J01F) 
Prescriptions 4650 0.58 377 0.54 1370 0.49 520 0.70 1737 0.58 163 1.13 483 0.84 
DDDs 34543 4.34 3089 4.41* 9229 3.29* 4738 6.34* 12674 4.24* 1114 7.74 3698 6.42 
Roxithromycin 
(J01FA06) 
Prescriptions 988 0.12 69 0.10 297 0.11 116 0.16 380 0.13 33 0.23 93 0.16 
DDDs 9611 1.21 631 0.90 2512 0.90 1055 1.41 3886 1.30 303 2.10 1226 2.13 
Azithromycin (J01FA10) Prescriptions 2219 0.28 157 0.22 681 0.24 235 0.31 816 0.27 73 0.51 257 0.45 
DDDs 10558 1.33 720 1.03 3219 1.15 1085 1.45 3806 1.27 340 2.36 1388 2.41 
Quinolone antibactrials 
(J01M) 
Prescriptions 1075 0.14 77 0.11 307 0.11 122 0.16 412 0.14 49 0.34 108 0.19 
DDDs 7094 0.89 575 0.82 1840 0.66 671 0.90 2686 0.90 478 3.32* 845 1.47* 
Other antibacterials 
(J01X) 
Prescriptions 116 0.02 5 0.01 50 0.02 9 0.01 43 0.01 1 0.01 8 0.01 
DDDs 2274 0.29 103 0.15 1206 0.43 100 0.13 783 0.26 1 0.01 81 0.14 
Antifungal drugs               
All (J02) Prescriptions 3010 0.38 162 0.23 771 0.27 406 0.54 1192 0.40 165 1.15 314 0.55 
DDDs 7800 0.98 501 0.72 1857 0.66 816 1.09 2981 1.00 649 4.5* 996 1.73* 
Fluconazole (J02AC01) Prescriptions 2602 0.33 138 0.20 665 0.24 357 0.48 1031 0.35 143 0.99 268 0.47 
DDDs 3943 0.50 265 0.38 894 0.32 486 0.65* 1316 0.44* 431 2.99 552 0.96 
Antiviral drugs               
All (J05) Prescriptions 893 0.11 73 0.10 190 0.07 149 0.20 317 0.11 19 0.13 145 0.25 
DDDs 3093 0.39 417 0.59 573 0.20 341 0.46 872 0.29 105 0.73 785 1.36 
Aciclovir (J05AB01) Prescriptions 677 0.09 63 0.09 150 0.05 92 0.12 246 0.08 15 0.10 111 0.19 
DDDs 2206 0.28 379 0.54 458 0.16 218 0.29 659 0.22 97 0.67 395 0.69 
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Appendix 2. Results of quasipoisson regression analyses with number of prescriptions as 
an outcome. 
 Estimate Standard Error P-value 
All Antimicrobial Drugs    
Intercept 0.05 0.102 0.610 
Age 0.02 0.002 <0.001 
Sex, female 0.67 0.089 <0.001 
Anorexia nervosa -0.07 0.053 0.190 
Bulimia nervosa 0.26 0.043 <0.001 
Binge-eating disorder 0.50 0.080 <0.001 
Antibacterial Drugs    
Intercept 0.16 0.096 0.100 
Age 0.01 0.002 <0.001 
Sex, female 0.52 0.082 <0.001 
Anorexia nervosa -0.05 0.051 0.320 
Bulimia nervosa 0.22 0.043 <0.001 
Binge-eating disorder 0.46 0.080 <0.001 
Antifungal Drugs    
Intercept -4.10 0.455 <0.001 
Age 0.03 0.004 <0.001 
Sex, female 2.18 0.437 <0.001 
Anorexia nervosa -0.34 0.162 0.030 
Bulimia nervosa 0.41 0.107 <0.001 
Binge-eating disorder 0.83 0.167 <0.001 
Antiviral Drugs    
Intercept -4.87 0.724 <0.001 
Age 0.05 0.008 <0.001 
Sex, female 1.27 0.660 0.060 
Anorexia nervosa 0.16 0.321 0.620 
Bulimia nervosa 0.68 0.236 0.004 
Binge-eating disorder -0.28 0.613 0.650 
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Appendix 3. Results of linear regression analysis with number of defined daily doses as an 
outcome. 
DDD, Defined Daily Dose 
 Estimate Standard Error P-value 
All Antimicrobial Drugs    
Intercept 9.47 4.421 0.032 
Age 0.27 0.087 0.002 
Sex, female 15.69 3.524 <0.001 
Anorexia nervosa 1.75 2.499 0.483 
Bulimia nervosa 10.53 2.421 <0.001 
Binge-eating disorder 30.30 5.375 <0.001 
Antibacterial Drugs    
Intercept 12.87 4.223 0.002 
Age 0.15 0.083 0.080 
Sex, female 14.08 3.370 <0.001 
Anorexia nervosa 1.44 2.390 0.548 
Bulimia nervosa 10.29 2.316 <0.001 
Binge-eating disorder 25.57 5.140 <0.001 
Antifungal Drugs    
Intercept -1.85 0.424 <0.001 
Age 0.07 0.008 <0.001 
Sex, female 0.91 0.338 0.007 
Anorexia nervosa -0.02 0.240 0.920 
Bulimia nervosa 0.16 0.232 0.490 
Binge-eating disorder 2.80 0.516 <0.001 
Antiviral Drugs    
Intercept -0.97 0.440 0.027 
Age 0.03 0.009 <0.001 
Sex, female 0.46 0.350 0.190 
Anorexia nervosa 0.33 0.249 0.188 
Bulimia nervosa 0.10 0.241 0.682 
 
Binge-eating disorder 0.01 0.535 0.979 
 
